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PETThe brains of patients suffering from Alzheimer3s disease (AD) have three classical pathological hallmarks:
amyloid-beta (Aβ) plaques, tau tangles, and neurodegeneration, including that of cholinergic neurons of the
basal forebrain. However the relationship between Aβ burden and basal forebrain degeneration has not been
extensively studied. To investigate this association, basal forebrain volumeswere determined frommagnetic res-
onance images of controls, subjects with amnesticmild cognitive impairment (aMCI) and AD patients enrolled in
the longitudinal Alzheimer3s Disease Neuroimaging Initiative (ADNI) and Australian Imaging, Biomarkers and
Lifestyle (AIBL) studies. In the AIBL cohort, these volumeswere correlatedwithin groups to neocortical graymat-
ter retention of Pittsburgh compound B (PiB) from positron emission tomography images as a measure of Aβ
load. The basal forebrain volumes of AD and aMCI subjects were signiﬁcantly reduced compared to those of
control subjects. Anterior basal forebrain volume was signiﬁcantly correlated to neocortical PiB retention in AD
subjects and aMCI subjects with high Aβ burden, whereas posterior basal forebrain volume was signiﬁcantly
correlated to neocortical PiB retention in control subjects with high Aβ burden. Therefore this study provides
new evidence for a correlation between neocortical Aβ accumulation and basal forebrain degeneration. In addi-
tion, cluster analysis showed that subjectswith awhole basal forebrain volume below a determined cut-off value
had a 7 times higher risk of having a worse diagnosis within ~18 months.
Crown Copyright © 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Alzheimer3s disease (AD) is a progressive neurodegenerative disor-
der that results in widespread brain atrophy of both gray and white
matter brain regions. Other hallmarks of the disease include the extra-
cellular deposition of amyloid-β (Aβ) and intracellular accumulation
of hyper-phosphorylated tau. An emerging method of early diagnosis
of AD is to assess brain Aβ burden through Pittsburgh compound BAD, Alzheimer3s disease; ADNI,
alian Imaging, Biomarkers and
itive impairment; CSF, cerebro-
ild cognitive impairment;MNI,
litymaps;MPRAGE,magnetiza-
ce imaging; OR, odds ratio; PET,
B;SPSS, statistics softwarepack-
tio; SyN, symmetric normaliza-
ating characteristic;WM,white
, The University of Queensland,
: +61 7 33466301.
r Inc. This is an open access article u(PiB)–positron emission tomography (PET) imaging. This measure
has shown promise in identifying people at risk of developing AD
(Villemagne et al., 2011); however, reports of correlations between
PiB retention and hippocampal atrophy, the magnetic resonance imag-
ing (MRI)measuremostwidely used togetherwith traditional cognitive
assessment for the diagnosis of AD (Frisoni et al., 2010), have been in-
consistent. Therefore it remains unclear what additional factors control
the progression to dementia of healthy subjects with high Aβ load.
Cholinergic neurons in the basal forebrain, a gray matter region lo-
cated in the medial and ventral aspects of the brain, provide the neuro-
transmitter acetylcholine to a variety of different brain regions. Anterior
basal forebrain nuclei, including the medial septum and diagonal band
send projections to the hippocampus, olfactory bulb, and piriform and
entorhinal cortices. Posterior basal forebrain nuclei, including the nucle-
us basalis of Meynert project to the amygdala and frontal, cingulate and
parietal cortices, as well as to the orbital and occipital cortices and the
temporal lobe (Mesulam et al., 1983; Zaborszky et al., 2008). Regulation
of acetylcholine supply to these brain regions is involved in local activa-
tion and modulation of plasticity, and cholinergic basal forebrain
neurons can therefore inﬂuence critical behaviors such as attention,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Demographics of the ADNI cohort. There was a signiﬁcant difference for age between the
AD and aMCI groups. Subject groups did not differ based on gender or years of education.
For representation of the healthy population we set CDR = 0 as the criterion for the HC
groups at baseline. Age and MMSE scores are expressed as mean ± SD.
ADNI study
HC aMCI AD
Number of subjects 69 127 30
Age 73.5 ± 6.7 72.3 ± 8.2 77.1 ± 7.5
Sex F/M 41/28 53/74 13/17
MMSE 28.9 ± 1.2 28.3 ± 1.5 23.4 ± 2.1
CDR 0 0–1 0.5–1
106 G.M. Kerbler et al. / NeuroImage: Clinical 7 (2015) 105–113learning andmemory (Mufson, 2003; Schliebs and Arendt, 2011). Post-
mortem assessment has revealed that signiﬁcant degeneration of these
neurons as an early pathological feature of ADpatients, and their degen-
eration,which is likely to underpin aspects of cognitive decline associat-
ed with the disease (Contestabile, 2011; Mesulam, 2004; Schliebs and
Arendt, 2011), drove the development of the now widely prescribed
acetyl cholinesterase inhibitor class of drugs. Consistent with this, re-
cent studies have demonstrated that AD patients, as well as patients
with mild cognitive impairment (MCI), a prodromal stage to AD, show
signiﬁcant basal forebrain volume loss compared to age-matched con-
trols (Grothe et al., 2012b; Hall et al., 2008; Muth et al., 2010), with at-
rophy of discrete regions within the basal forebrain being signiﬁcantly
associated with global cognitive decline as well as delayed recall scores
in AD subjects (Grothe et al., 2010). Although the basal forebrain has
been shown to degenerate in normal aging, the rate of atrophy is signif-
icantly higher in subjects suffering fromdementia (Grothe et al., 2012a),
and speciﬁc areas within the basal forebrain appear to be particularly
vulnerable to AD-associated degeneration (Grothe et al., 2012b).
An association between basal forebrain atrophy and Aβ burden in
AD has recently been reported using MRI and AV45-PET data (Grothe
et al., 2014; Teipel et al., 2014) acquired from the Alzheimer3s Disease
Neuroimaging Initiative (ADNI) cohort. In this study we also found a
signiﬁcant association between basal forebrain atrophy, based on a his-
tologicalmask restricted to AD-speciﬁc degeneration, and Aβ load using
PiB–PET, including a correlation between these hallmarks that extends
to healthy control subjects of the Australian Imaging, Biomarkers and
Lifestyle (AIBL) cohort (Ellis et al., 2009). Furthermore, we determined
that degeneration of the basal forebrain is a signiﬁcant risk factor for
further cognitive decline in control and MCI cohorts, irrespective of Aβ
burden.
2. Materials and methods
2.1. Subjects
Data analyzed for this report were obtained from the AIBL study
(Ellis et al., 2009) (http://www.aibl.csiro.au/) and the ADNI study
(http://adni.loni.ucla.edu). From the AIBL study, longitudinal PiB and
3T T1-weighted (T1W) MRI images of AD, amnestic MCI (aMCI) and
healthy control (HC) subjects at two time-points (Table 1) were used.
The HC and aMCI groups were further subdivided into subjects with
high (PiB+) and low (PiB−) PiB retention levels, as previously reported
(Villain et al., 2012). The methodology for cohort recruitment and eval-
uation has been reported elsewhere (Ellis et al., 2009). From the ADNI-
2/GO study, 3 T T1WMRI images of HC, aMCI and AD subjects (Table 2)
were examined.
2.2. Imaging protocol
From the ADNI cohort, 3 T MR images were acquired using themag-
netization prepared rapid gradient echo (MPRAGE) imaging protocol inTable 1
Demographics of AIBL cohort at baseline and followup. Numbers in brackets at baseline indicate
the HC PiB− and HC PiB+ subjects(p b 0.05), as well as the HC PiB− and aMCI(p b 0.001) sub
mental state examination (MMSE) scores between aMCI/AD and all other groups were signiﬁca
resentation of the healthy population we set clinical dementia rating (CDR) = 0 as the criterio
AIBL study
Baseline
HC PiB- HC PiB+ aMCI AD
Number of subjects 101 (89) 44 (35) 40 (21) 38 (
Age 71.1 ± 6.7 75.1 ± 6.8 76.5 ± 7.2 72.5
Sex F/M 57/44 23/21 20/20 22/
MMSE 28.8 ± 1.2 28.8 ± 1.2 27.3 ± 2.2 20.6
CDR 0 0 0.5 0.5–accordance with ADNI’s guidelines for these scans (http://adni.loni.usc.
edu/methods/documents/mri-protocols). For the AIBL cohort, 3 T MR
structural images were acquired on a Siemens 3 T Trio. Participants
received an MRI scan using the ADNI 3D MPRAGE sequence, with
1 × 1 mm in-plane resolution and 1.2 mm slice thickness, TR/TE/T1 =
2300/2.98/900, ﬂip angle 9° and ﬁeld of view 240 × 256 and 160 slices.
In addition, each AIBL subject received ~370MBqPiB intravenously over
1 min. A 30-minute acquisition in 3-dimensional (3D) mode starting
40 min after injection of PiB was performed with a Philips Allegro PET
camera. A transmission scan was performed for attenuation correction.
PET images were reconstructed using a 3D RAMLA algorithm.
2.3. MRI processing
The hippocampus, pons and gray matter (GM), white matter (WM)
and cerebrospinal ﬂuid (CSF) were segmented from the MPRAGE
images using the method outlined in Bourgeat et al. (2010). A skull
strip mask was generated from the GM, WM and CSF segmentation.
All volume calculations reported are normalized by intracranial volume.
Using the AIBL study data, the skull-stripped MPRAGE images of all
subjects were normalized to create an average elderly template brain
using the open-source deformable registration tool ANTS. ANTS pro-
vides functionality for generating optimal templates, given a collection
of images, which offers advantages over a priori templates for image
normalization (for instance in the hippocampus; Avants et al., 2010).
The population-speciﬁc template was generated by iteratively register-
ing images to the current template estimate. A new shape and intensity
average were then computed from the results of the registrations and
the current template estimatewas set as the average. This template gen-
eration procedure was repeated iteratively (I = 5). Each registration in
this procedure used the greedy symmetric normalization algorithm
(SyN, parameters outlined below) and the cross-correlation after
subtracting the local mean from the image match metric. A z-score
map of the deformation ﬁeld of the AD subjects with HC subjects from
the AIBL cohort was generated.
The registration between each subject3s MPRAGE image (AIBL and
ADNI) and the population-speciﬁc template was performed using the
SyN algorithm (GradStep = 0.5, regularization sigma = 2.0). Thethenumber of subjects used for calculation of longitudinal changes. At baseline, the ages of
jects, were signiﬁcantly different. There was no gender difference between groups. Mini-
ntly different. Years of education were not signiﬁcantly different between groups. For rep-
n for the HC groups at baseline. Age and MMSE scores are expressed as mean ± SD.
Follow up (~18 months)
HC PiB− HC PiB+ aMCI AD
16) 83 39 17 22
± 8.5 72.2 ± 6.5 74.9 ± 7.0 77.0 ± 6.8 74.3 ± 7.9
16 49/34 14/25 9/8 11/11
± 5.2 28.8 ± 1.4 28.5 ± 1.5 27.4 ± 2.0 20 ± 5.7
3 0 0–0.5 0–0.5 0.5–2
107G.M. Kerbler et al. / NeuroImage: Clinical 7 (2015) 105–113image match metric was the cross-correlation between the images.
Cross-correlation after subtracting the local mean from the image at
each voxel was computed using a 5 × 5 × 5 voxel window. Registration
was performed in a multi-resolution scheme, with a maximum of 30
iterations at 4× subsampling, 90 iterations at 2× subsampling, and 50
iterations at full resolution.
To establish basal forebrain masks encompassing only those areas
that undergo atrophy in AD patients (Fig. 1), we compared all control
and AD subjects from the AIBL cohort and overlaid the resultant
z-score map (set to−0.5 and−1 standard deviations) on a standard
Montreal Neurological Institute (MNI) brain (z-score map, Fig. 1A, B).
Using published probabilistic basal forebrain maps derived from histo-
logical data as a guide for the limits of the structure (Zaborszky et al.,an
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Fig. 1. Basal forebrain masks of AD-speciﬁc changes in template space. Coronal slices illustratin
paring theHC andADgroups in theAIBL study. In the lower rows (A, B), amagniﬁedviewof the b
basal forebrain volumes. The BF rawmask (red; A, B)was used as a combination of the anterior a
A, B) was used both as a combination of the anterior and posterior regions, and the anterior a
different levels from rostral to caudal are shown in A and B, on a T1-weighted image. BF = bas2008), we then manually segmented the regions of atrophy within the
standard space corresponding to the basal forebrain area. Using this
method we created two types of basal forebrain masks.
First, we used published raw probabilistic maps (Zaborszky et al.,
2008) from at least one post-mortem brain as a guide, resulting in a
basal forebrain mask covering a large number of basal forebrain voxels
(BF raw; size: 3193 voxels; Fig. 1A, B) and a ﬁnal delineated area of in-
termediate anatomical speciﬁcity. Second, we usedmaximumprobabil-
itymaps (MPMs; Zaborszky et al., 2008) as guidance, resulting in a basal
forebrainmask covering voxels that were identiﬁed as lying in the basal
forebrain in ten post-mortem brains (BF MPM; size: 1160 voxels;
Fig. 1A, B) and a ﬁnal delineated area of high anatomical speciﬁcity.
One aim of this study was to assess and compare the sensitivity ofy=8886 y=90
y=98 y=10096
g the z-score map on a whole template brain (blue; top row A and B) calculated by com-
asal forebrain area is shown to better illustrate the z-scoremap (blue) aswell as individual
nd posterior parts for analysis of thewhole basal forebrain area. The BFMPMmask (green;
nd posterior regions individually, to analyze the basal forebrain area. The same slices at
al forebrain, MPM=maximum probability map.
108 G.M. Kerbler et al. / NeuroImage: Clinical 7 (2015) 105–113both BF raw andMPMmasks in detecting volumetric changes aswell as
identifying associations with global Aβ burden. To study anterior and
posterior basal forebrain compartments separately, we further divided
the BF MPM map into an anterior BF MPM volume (size: 595 voxels;
Fig. 1A), covering Ch1–3 as well as Ch4 anterior cell groups, and a pos-
terior BFMPMvolume (size: 565 voxels; Fig. 1B), covering Ch4 interme-
diate and posterior cell groups (nomenclature according to Mesulam
et al., 1983). The ﬁnal BF raw and BF MPM masks comprised areas
throughout the entire extent of the basal forebrain area (Ch1–4 cell
groups) and were validated by overlaying the masks onto newly devel-
oped raw probabilistic and MPM basal forebrain post-mortem maps
(Eickhoff et al., 2005, 2006, 2007), respectively. This showed an overlap
of 50% for the BF raw mask with the raw probabilistic post-mortem
map, an overlap of 85% for the BF MPMmap with the raw probabilistic
post-mortem map and an overlap of 46% for the BF MPMmap with the
MPM post-mortem map. Neither the BF raw nor the BF MPMmap was
speciﬁc for cholinergic cells of the basal forebrain, but rather represent-
ed the general basal forebrain area. Using the aforementioned registra-
tion between the subject and atlas, the basal forebrain masks were
propagated into the subjects’ space and any voxels labeled as CSF
(from CSF segmentation) were removed. The resulting mask was then
used to extract the GM volume.
Because the basal forebrain masks were created based on atrophy
maps derived from comparing AD and control subjects from the AIBL
cohort, we tested whether the BF rawmask was able to detect changes
in the AIBL cohort as well as in an independent cohort, namely the ADNI
cohort (Fig. 2). This analysis revealed similar changes between AD and
control subjects as well as AD and aMCI subjects in both cohorts.
2.4. PET image processing
The PET images were processed as described by Bourgeat et al.
(2010). In summary, PET and MR images were co-registered. The PiB
images were standard uptake value ratio (SUVR) normalized (pons
WM) with PiB+ deﬁned as SUVR N 0.71 (Villain et al., 2012) and neo-
cortical PiB retention calculated within the GM segmentation.
2.5. Statistical analysis
The Statistics Software Package for the Social Sciences (SPSS, v20.0)
was used to determine signiﬁcant differences and correlations.
Group comparisons were performed using ANOVA followed by the
Bonferroni post-hoc test. The parameters compared between groups
were corrected for age. Partial correlations controlling for age were
used to determine signiﬁcant associations between parameters. There
was no signiﬁcant difference for sex or years of education between
groups. Basal forebrain volume, hippocampal volume and neocorticalA
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Fig. 2. Group comparisons of basal forebrain volume in the AIBL and ADNI study cohorts. In the
groups compared to controls. In the ADNI study (B), the basal forebrain volume of the AD subje
brain Volumes of the aMCI groups display high variability in both study cohorts. *** p b 0.001.W
ranges away from the 75th percentile.PiB retention values were signiﬁcantly correlated to age but not sex or
years of education.
Hierarchical cluster analysis was used to determine the basal fore-
brain volumes that distinguished discrete clusters. Two-step cluster
analysis automatically identiﬁed three existing clusters in the basal
forebrain volume data, and both non-hierarchical (K-means) cluster
analysis and two-step cluster analysis provided highly similar cluster
groups. The two-graph receiver operating characteristic (TG-ROC) was
used to determine cut-off values between clusters (Greiner, 1995).
The odds ratio (OR) was calculated to determine the probability of sub-
jects beingwithin the high/medium vs. low-risk basal forebrain volume
group at baseline if their diagnosis worsened at follow-up. A chi-square
test was used to determine the signiﬁcance of this ratio.
3. Results
3.1. Differences in basal forebrain volume between HC, aMCI and AD
subjects
To measure basal forebrain atrophy in this study, four different
masks were used (Fig. 1). These masks were based on raw probabilistic
(BF raw) and MPM maps (BF MPM, BF MPM anterior and BF MPM
posterior) of post-mortem delineations of the basal forebrain, and
further restricted to represent basal forebrain areas found to undergo
atrophy in AD subjects versus age-matched controls. The results of
group comparisons of BF raw volumes in the AIBL and ADNI cohorts
(Fig. 2) and group comparisons of BF MPM volumes in the AIBL cohort
(Table 3) are shown. All basal forebrain volumes of the AD group were
signiﬁcantly less than those of HC subjects. In addition AD subjects
had signiﬁcantly smaller basal forebrain volumes than aMCI subjects.
The BF raw volumes between the HC and aMCI groups in the ADNI co-
hort were not signiﬁcantly different. Furthermore all basal forebrain
volumes of aMCI subjects were signiﬁcantly smaller than those of HC
PiB− subjects (control subjects showing low PiB retention values), but
only the BF raw volume of aMCI subjects was signiﬁcantly different
from that of HC PiB+ subjects (control subjects showing high PiB
retention values). To test whether controls at risk of developing AD, ac-
cording to PiB retention status, namely HC PiB+ subjects, had smaller
basal forebrain volumes than HC PiB− subjects, we compared the two
groups. No signiﬁcant difference in the mean basal forebrain volume
between the HC PiB+ and HC PiB− groups was detected.
3.2. Correlation between whole basal forebrain volumes and neocortical
amyloid burden
To determine whether the volume of the whole basal forebrain area
was correlated to the neocortical amyloid level measured by PiB–PETB ADNI study cohort
ADaMCIHC
.0020
.0018
.0016
.0014
.0012
.0010
***
AIBL (A) study, the basal forebrain volumewas signiﬁcantly decreased in the AD and aMCI
ct groupwas signiﬁcantly smaller than that of the HC and aMCI subject groups. Basal fore-
hiskers represent min/max values except data points (circles)more than 1.5 interquartile
Table 3
p-Values of group comparisons of basal forebrain volumes in the AIBL cohort. All volumes
were signiﬁcantly different between the AD and control, AD and aMCI aswell as aMCI and
HC PiB− groups, whereas only the BF raw volumewas signiﬁcantly different between the
aMCI and HC PiB+ subjects. BF = basal forebrain, MPM=maximum probability map.
Volume AD vs
HC PiB+
AD vs
HC PiB−
AD vs
aMCI
aMCI vs
HC PiB+
aMCI vs
HC PiB−
HC PiB+ vs
HC PiB−
BF raw b0.001 b0.001 0.002 0.02 b0.001 1.0
BF MPM b0.001 b0.001 0.001 0.151 0.002 1.0
BF MPM
anterior
b0.001 b0.001 0.026 0.066 0.001 1.0
BF MPM
posterior
b0.001 b0.001 0.021 0.393 0.001 0.385
Table 4
Correlations of basal forebrain volumes to the neocortical PiB retention values in groups of
the AIBL cohort. Signiﬁcant interactions were found for BF raw and BFMPM posterior vol-
umes in the HC PiB+ group, whereas BF raw and BF MPM anterior volumes showed sig-
niﬁcant interactions in the AD group. Only the BF MPM anterior volume was
signiﬁcantly correlated to neocortical PiB retention in aMCI PiB+ subjects. BF=basal fore-
brain, MPM=maximum probability map.
Volume All
subjects
HC
PiB−
HC
PiB+
aMCI aMCI
PiB+
AD
BF raw r 0.47 0.09 0.32 0.18 0.33 0.39
p-Value b0.001 0.36 b0.05 0.27 0.12 b0.05
BF MPM r 0.46 0.17 0.24 0.26 0.39 0.32
p-Value b0.001 0.1 0.12 0.11 0.066 0.053
BF MPM
anterior
r 0.43 0.17 0.06 0.23 0.43 0.42
p-Value b0.001 0.1 0.71 0.16 b0.05 b0.05
BF MPM
posterior
r 0.44 0.13 0.33 0.25 0.29 0.22
p-Value b0.001 0.19 b0.05 0.12 0.19 0.19
109G.M. Kerbler et al. / NeuroImage: Clinical 7 (2015) 105–113we performed partial age-controlled correlations between the two
measures in the AIBL cohort. Scatter plots of BF raw volume correlations
are shown in Fig. 3 and r- and p-values of BF raw aswell as BFMPM vol-
umes are listed in Table 4.We found that, on average, subjectswith high
Aβ burden, regardless of clinical diagnosis, had smaller BF raw and BF
MPM volumes, whereas subjects with low Aβ burden had basal fore-
brain volumes in the normal range. Correlations in individual groups,
namely in the HC (PiB+ and PiB−), aMCI (PiB+ and PiB−) and AD
groups revealed that the BF raw volume was correlated to the neocorti-
cal PiB retention value in the AD (r=0.39; p b 0.05) and HC PiB+ (r=
0.31; p b 0.05) groups, but not in the aMCI PiB+ (r= 0.33; p= 0.12),
aMCI PiB− (r = 0.17; p = 0.55) and HC PiB− (r = 0.09; p = 0.36)
groups. In contrast, neither BF MPM volume, nor hippocampal volumeBasal forebrain volume
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Fig. 3. Correlation of BF raw volume (x-axis) to neocortical PiB retention (y-axis) in the AIBL st
(A) aswell for individual subject groups (B–E). The cut-off value used to determine high and low
Signiﬁcant interactions were observed in the HC PiB+ (C) and AD (D) subject groups. Even tho
signiﬁcant. A linear ﬁt line with 95% conﬁdence interval is shown.(data not shown), was correlated to the neocortical PiB retention in
any of the abovementioned groups.
3.3. Correlation between anterior/posterior basal forebrain volumes and
neocortical amyloid burden
The anterior basal forebrain volume (BF MPM anterior) represents
the medial septum (Ch1 nucleus) and the vertical (Ch2 nucleus) and
horizontal diagonal band of Broca (Ch3 nucleus), as well as anterior
parts of the nucleus basalis of Meynert (Ch4 nucleus). This volumeBasal forebrain volume
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Fig. 4. Signiﬁcant correlations of anterior and posterior BF MPM posterior Volumes (x-axis) to neocortical PiB retention (y-axis) in the AIBL study. Whereas BF MPM anterior volume
showed signiﬁcant correlations in aMCI PiB+ (A) and AD (B) subjects, BFMPMposterior volumewas signiﬁcantly correlated to neocortical PiB retention in HC PiB+ (C) subjects. A linear
ﬁt line with 95% conﬁdence interval is shown.
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Fig. 5. Delineations based on basal forebrain cluster analysis using the BF raw volume,
highlighting the subjects in the AIBL study whose diagnosis worsened (‘converters’).
In the AIBL study. Basal forebrain cut-off values of 0.00145 and 0.00163 were deter-
mined by hierarchical cluster analysis to distinguish three clusters (delineated by
vertical dashed lines); the PiB cut-off value of 0.71 is indicated by the horizontal
dashed line. Subjects are colored according to their group status at baseline. The mean
basal forebrain volume for each group is as follows (given in mean ± SD): AD:
0.001414 ± 0.000138; aMCI: 0.001525 ± 0.000184; HC PiB+: 0.001612 ± 0.000089;
HC PiB−: 0.001629 ± 0.000123. The converters are indicated by the diamond-shaped
(conversion to AD), triangular (conversion to aMCI) and circular (reversion to HC) data
points, with the ﬁll showing the group status at baseline. All but one HC PiB+ to aMCI
converting subject fall into the high or medium risk clusters. The subject reverting from
aMCI to HC PiB+ group status is shown as a circular data point with a black border.
aMCI to AD = aMCI diagnosis at baseline, AD diagnosis at follow up; aMCI to HC
PiB+ = aMCI diagnosis at baseline, HC PiB+ diagnosis at follow up; HC PiB+ to AD =
HC PiB+ diagnosis at baseline, AD diagnosis at follow up; HC (PiB+ or PiB−) to
aMCI = HC diagnosis at baseline, aMCI diagnosis at follow up.
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when pooling all subjects together (r=0.43; p b 0.001), aswell as in the
AD (r= 0.42; p b 0.05) and aMCI PiB+ (r= 0.43; p b 0.05) groups but
not theHCPiB+ (r=0.06; p=0.71) group alone. Notably the posterior
basal forebrain volume (BF MPM posterior), corresponding to interme-
diate and posterior parts of the NbM (Ch4 nucleus), was correlated to
neocortical PiB retention (Fig. 4, Table 4) in all subjects (r = 0.44;
p b 0.001) and HC PiB+ subjects (0.33; p b 0.05) alone, but not in the
aMCI PiB+ (r = 0.29; p = 0.19) and AD (r = 0.22; p = 0.19) subject
groups. There was no correlation of either BF MPM anterior or BF
MPM posterior volume to neocortical Aβ burden in the HC PiB− and
aMCI PiB− groups.
3.4. Basal forebrain cluster analysis for diagnosis of converters
To test the diagnostic potential of basal forebrain volume in identify-
ing subjects at risk of converting from either HC to aMCI, or aMCI to AD
clinical status, we performed cluster analysis of basal forebrain volume
(BF raw) in the AIBL (Fig. 5) and ADNI (data not shown) cohorts using
all subjects, irrespective of diagnostic status. Three clusters of normal,
reduced and low basal forebrain volume were revealed, and similar
cut-off values were found to separate the clusters in both study cohorts.
The mean basal forebrain volume of the AD and the aMCI groups fell
into the low and reduced basal forebrain volume clusters, respectively.
In addition, the mean basal forebrain volume of the HC subjects who
were PiB+ fell within the reduced basal forebrain cluster. Moreover,
in both the AIBL and ADNI cohorts, the basal forebrain volumes of
subjects whose diagnosis changed from either HC to aMCI (AIBL,
n = 3), HC to AD (AIBL, n = 1) or aMCI to AD (AIBL, n = 5; ADNI,
n = 3) were found in either the low or reduced basal forebrain vol-
ume group (with the exception of one PIB+ aMCI subject). Cluster
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1 PiB− subject, whose diagnosis worsened, fell in either the low or re-
duced hippocampal volume cluster. Finally, we found that the risk of
having a worse diagnosis within ~18 months (based on calculations
using AIBL data) was signiﬁcantly greater (OR = 7.2; chi-squared =
4.53, p b 0.05) for subjects falling into either the low or reduced basal
forebrain volume category, as compared to subjects with a basal fore-
brain volume in the normal range.
3.5. Neocortical and cerebellar volume group comparisons and correlations
with basal forebrain volume
The AD group was found to have a signiﬁcantly reduced mean neo-
cortical volume as compared to the HC PiB+ group (Table 5). There
were no other neocortical volume differences between groups, and
cerebellar volumes were not signiﬁcantly reduced in any of the subject
groups (Table 5). To assess whether basal forebrain atrophy was associ-
atedwith neocortical atrophy or cerebellar volume, correlations of basal
forebrain volumes with neocortical and cerebellar volumes were per-
formed. No signiﬁcant correlation of basal forebrain volume to either
neocortical or cerebellar volume was found.
4. Discussion
Despite AD being characterized by both accumulation of Aβ and at-
rophy of the basal forebrain, the relationship between these two patho-
logical features has not been widely investigated within independent
patient cohorts. We conﬁrm the ﬁndings recently published using data
from the ADNI cohort (Grothe et al., 2014; Teipel et al., 2014) and dem-
onstrate here that whole basal forebrain volume signiﬁcantly correlates
with neocortical Aβ burden, measured through PiB retention, in AD and
HC PiB+ groups. In the HC PiB+ group, neocortical Aβ burden corre-
lates with posterior basal forebrain volume, whereas in aMCI PiB+
and AD groups, neocortical Aβ burden correlates with anterior basal
forebrain volume. Furthermore, subjects who retrospectively converted
from a diagnosis of either HC to aMCI or aMCI to ADwere found to have
reduced basal forebrain volumes prior to conversion. These ﬁndings
provide validity to emerging human and animal studies demonstrating
a link between cholinergic basal forebrain neuron degeneration and Aβ
production and/or deposition (Gil-Bea et al., 2012; Grothe et al., 2014;
Ramos-Rodriguez et al., 2013; Teipel et al., 2014).
The interaction between basal forebrain volume and neocortical Aβ
burden was studied using whole, anterior or posterior basal forebrain
masks created by delimiting those areas found to undergo atrophy in
AD subjects (versus age-matched controls) within the basal forebrain
area. However the ﬁnal masks showed only partial overlap with
not yet publicly available post-mortem maps, developed by Eickhoff
(Heinrich-Heine University, Düsseldorf) and colleagues, being signiﬁ-
cantly larger;We acknowledge that this may represent areas of atrophyTable 5
Results of neocortical and cerebellar volume analysis in the AIBL cohort. Average volumes, grou
There was a signiﬁcant difference for neocortical volume between the AD and HC PiB+ group (
volume and no signiﬁcant correlation of basal forebrain volume to either neocortical or cerebe
Neocortex
Group
Volume Group comparisons Correlation (
Vs p-Value
HC PiB− 0.433 ± 0.021 HC PiB+ 0.3 0.14
aMCI 1.0
AD 0.53
HC PiB+ 0.440 ± 0.018 aMCI 1.0 0.08
AD 0.02 *
aMCI 0.437 ± 0.019 AD 0.13 0.14 (0.18)a
AD 0.426 ± 0.022 HC PiB± 0.02 * 0.12
a Correlation value for the aMCI PiB+ group is shown in bracket.
* Signiﬁcant difference at p b 0.05.in anatomically close brain regions in some subjects, but nonetheless,
we reasoned that this method of estimating basal forebrain volume
may provide increased sensitivity to detect change in AD over the pure-
ly post-mortem-based segmentations previously used by others. In-
deed, the results of our volumetric analysis using the atrophy-based
whole basal forebrain mask are consistent with the ﬁndings of previous
studies inwhich subnuclei of the basal forebrain or closely located brain
regionswere analyzed (Grothe et al., 2010, 2012a,b), with differences in
average basal forebrain volume being detected when comparing
healthy controls to AD, very mild AD, and MCI groups. The analysis of
the ADNI cohort shown here (Fig. 2) further supports data presented
previously (George et al., 2011). Interestingly, there was a signiﬁcant
difference between aMCI and HC PiB+ groups for BF raw but not BF
MPM volumes in the AIBL cohort. This might be explained by the fact
that the BF raw volume is almost three times the size of the BF MPM
volume and may therefore be more sensitive to overall changes. The
absence of a signiﬁcant correlation between basal forebrain volume
and either neocortical volume or cerebellar volume (Table 5) further
strengthens the speciﬁcity of basal forebrain degeneration assessed by
our measurements as a feature of AD pathology.
In order to investigate whether the correlations between whole
basal forebrain volume with neocortical PiB retention observed in this
study were driven by interactions with sub-areas of the basal forebrain,
we performed correlations of the anterior (Ch1, Ch2, Ch3 and Ch4 ante-
rior nuclei) and posterior (Ch4 intermediate and posterior nuclei) basal
forebrain volumes with neocortical PiB retention. In the earliest stages
of AD the posterior and intermediate parts of the Ch4 cell group,
which are represented by the BF MPM posterior volume in this
paper, are the regions predominantly affected by pathological changes
(Grothe et al., 2012b). The posterior basal forebrain nuclei send projec-
tions to the temporal lobe, amygdala, occipital and orbital cortices, as
well as to brain regions subject to heavyAβ deposition, such as the fron-
tal, cingulate and parietal cortices (Klunk et al., 2004). Furthermore, loss
of cholinergic innervation to the aforementioned regions was recently
found in vivo in MCI patients (Haense et al., 2012). Thus it is signiﬁcant
that we found a correlation between posterior basal forebrain volume
and neocortical PiB retention in the HC PiB+ group, a cohort which rep-
resents a control subgroup that might be at high risk of developing AD.
We also observed signiﬁcant correlations of neocortical PiB retention
with BF MPM anterior volume in the aMCI PiB+ and AD groups. In this
study, even though the BF raw mask was more sensitive than the BF
MPM maps in identifying volumetric differences between groups, BF
MPM volumes showed higher correlation coefﬁcients and identiﬁed
additional signiﬁcant interactions with neocortical PiB retention as
compared to the associations with BF raw volume. In addition, raw
probabilistic maps have been shown to be at risk of misclassifying
voxels, whereas MPM maps should not suffer from this limitation
despite showing similar sensitivity (Eickhoff et al., 2006). Therefore
we recommend the use of BF MPM maps, particularly subregionalp comparisons and correlation coefﬁcients of each structure to BF raw volumes are shown.
denoted by *), but not between other groups. We did not ﬁnd differences in the cerebellar
llar volume was found. Volumes are expressed as mean ± SD.
Cerebellum
r) Volume Group comparisons
Correlation (r)
Vs p-Value
0.011 ± 0.001 HC PiB+ 1.0 0.08
aMCI 1.0
AD 1.0
0.011 ± 0.001 aMCI 1.0 0.02
AD 1.0
0.011 ± 0.001 AD 1.0 0.28 (0.1)a
0.010 ± 0.001 HC PiB± 0.14 0.05
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global Aβ burden and basal forebrain volumes.
The associations between basal forebrain volumes and amyloid
burden presented in this work are consistent with previous reports of
a correlation between AV45 retention and basal forebrain volume
(Grothe et al., 2014), and the ﬁnding that, as subjects progress to aMCI
andAD clinical status, changes in anterior basal forebrain areas, contain-
ing nuclei that project to the hippocampus, olfactory bulb and piriform
and entorhinal cortices, becomemuch more pronounced (Grothe et al.,
2012b). In linewith this are also recent studies demonstrating choliner-
gic neuronal dysfunction in the cerebral cortex in MCI and AD based on
the use of PET to assess the activity of the key cholinergic enzyme
acetylcholine esterase. Acetylcholine esterase is primarily membrane-
bound and located on presynaptic cholinergic neurons, and its activity
is known to reﬂect the integrity of the ascending cholinergic system
(Garibotto et al., 2013). Degeneration of the cortical cholinergic projec-
tion system arising from posterior basal forebrain nuclei, represented
by the posterior mask in this paper, was found to occur at early stages
of dementia (Haense et al., 2012; Herholz et al., 2008). This is consistent
with early dysfunction of posterior nucleus basalis of Meynert neurons,
and acetylcholine esterase activity in temporal lobe regions has
also been correlated to memory impairment in MCI and AD patients
(Haense et al., 2012; Marcone et al., 2012).
While the correlations between basal forebrain volume and neocor-
tical PiB retention reported here maymerely reﬂect the progressive na-
ture of basal forebrain atrophy occurring independently of increasing
Aβ load, we hypothesize that this is not the case. Firstly, Aβ burden
does not correlate with atrophy of other brain areas, including the
hippocampus. Previouswork using data from the AIBL study has report-
ed a correlation between hippocampal volume and temporal neocorti-
cal PiB retention in the HC PiB+ group (Bourgeat et al., 2010) and
subjective cognitively impaired subjects (Chetelat et al., 2010). Howev-
er, no correlationswere found for the ADor theMCI groups, and atrophy
of the hippocampus did not correlate with hippocampal PiB retention in
another AIBL study (Rowe et al., 2010). Furthermore, similar analyses of
AIBL subjects, performed in the present study, failed to reveal any corre-
lation between hippocampal volume and neocortical PiB retention in
any subject group (data not shown). Moreover, the correlation in the
AD group between BF raw volume and PiB retention increased from
r = 0.39 to r = 0.42 when controlling for hippocampal volume. This
indicates that the relationship between basal forebrain volume and Aβ
deposition is not driven purely by reduced hippocampal volume, even
though these volumes are strongly correlated (data not shown).
Furthermore, in agreement with our ﬁndings, a recent study sug-
gested that basal forebrain atrophy can predict cortical amyloid burden,
and ismore closely associatedwith cortical amyloid burden than hippo-
campal atrophy (Teipel et al., 2014). Secondly, a causal relationship is
supported by emerging studies in animal models of AD inwhich cholin-
ergic basal forebrain neuron shrinkage, synaptic loss and axonal degen-
eration partly caused by, or causing, Aβ deposition in the brain,
have been reported (Gil-Bea et al., 2012; Knowles et al., 2009; Ramos-
Rodriguez et al., 2013; Sotthibundhu et al., 2008). Although our basal
forebrainmeasurements encompass a structurewhich is heterogeneous
in nature, the cholinergic neurons of the basal forebrain are preferential-
ly lost in AD (Mufson, 2003) and their degeneration could, at least
partly, account for the observed reduction in basal forebrain volume. It
also remains to be determined what other factors might correlate with
or drive basal forebrain volume loss and/or Aβ burden. Of particular
relevance is the development of tau pathology that occurs in basal fore-
brain neurons (Braak et al., 2006; Braak and Del Tredici, 2004, 2011).
Tau pathology is more strongly associated with cognitive decline
(Braak and Braak, 1991) and is likely to have pronounced effects on
basal forebrain volumetric measures.
Regardless of the cause of the observed basal forebrain volume loss,
in support of the assertion that early basal forebrain atrophy is a key
disease hallmark, cluster analysis of raw BF volume, including analysisof subjects whose diagnosis converted tomore cognitively impaired, re-
vealed that most subjects converting from HC to aMCI or from aMCI to
AD had a low basal forebrain volume prior to conversion. All converters
in both the AIBL andADNI studies (with the exception of one aMCI PiB+
subject) fell into the low or reduced basal forebrain volume clusters
prior to conversion, which could be considered to be the high/medium
risk categories. In the AIBL study the mean basal forebrain volumes of
AD subjects fell into the low volume cluster whereas mean basal fore-
brain volumes of the aMCI, HC PiB+ and HC PiB+ groups fell into the
reduced volume cluster. Subjects in the latter groups were found in all
3 vol clusters indicating that the range of basal forebrain volumes is
large even in non-demented elderly subjects, which is a limitation of
using only basal forebrain volumetricmeasures for diagnostic purposes.
Neverthelesswe found that subjects belonging to the high/medium risk
categories in the AIBL study were 7.2 times more likely to convert to
more cognitively impaired than subjects in the low risk category. Inter-
estingly, 3 of the normal controls in themedium risk categorywhowere
cognitively impaired at follow up were PiB− at the time of baseline
diagnosis, again indicating that basal forebrain atrophy might be a pre-
clinicalmarker of dementia, albeit that these peoplemay not progress to
AD. Although the sample size used to assess basal forebrain volumes for
risk of conversion was small, and additional longitudinal data are re-
quired to verify our ﬁndings, the signiﬁcant cumulative evidence for
basal forebrain atrophy being observed in life in AD clinical cohorts
provides increasing impetus for including basal forebrain volume in
the general “atrophy signature” for the diagnosis of patients at risk
of, or with, AD. Furthermore, basal forebrain measures used in con-
junction with other disease markers, such as Aβ load (Kim et al.,
2012; Villemagne et al., 2011), may further delineate subjects at risk
of progressing to AD or those for whom other interventions, including
anti-Aβ treatments, may be of most beneﬁt.
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